6.
McCulloch D, Marmor M, Brigell M, Hamilton R, Holder G, Tzekov R
. ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol. 2014; 130(1):1-12.
DOI: 10.1007/s10633-014-9473-7.
View
7.
Hanif A, Armenti S, Taylor S, Shah R, Igelman A, Jayasundera K
. Phenotypic Spectrum of Pentosan Polysulfate Sodium-Associated Maculopathy: A Multicenter Study. JAMA Ophthalmol. 2019; 137(11):1275-1282.
PMC: 6735406.
DOI: 10.1001/jamaophthalmol.2019.3392.
View
8.
Uner O, Shah M, Jain N
. PENTOSAN POLYSULFATE AND VISION: Findings from an International Survey of Exposed Individuals. Retina. 2020; 41(7):1562-1569.
PMC: 8200367.
DOI: 10.1097/IAE.0000000000003078.
View
9.
Shah R, Simonett J, Lyons R, Rao R, Pennesi M, Jain N
. Disease Course in Patients With Pentosan Polysulfate Sodium-Associated Maculopathy After Drug Cessation. JAMA Ophthalmol. 2020; 138(8):894-900.
PMC: 7349079.
DOI: 10.1001/jamaophthalmol.2020.2349.
View
10.
Spirn M, Warren F, Guyer D, Klancnik J, Spaide R
. Optical coherence tomography findings in nicotinic acid maculopathy. Am J Ophthalmol. 2003; 135(6):913-4.
DOI: 10.1016/s0002-9394(02)02296-1.
View
11.
Wang D, Velaga S, Grondin C, Au A, Nittala M, Chhablani J
. Pentosan Polysulfate Maculopathy: Prevalence, Spectrum of Disease, and Choroidal Imaging Analysis Based on Prospective Screening. Am J Ophthalmol. 2021; 227:125-138.
DOI: 10.1016/j.ajo.2021.02.025.
View
12.
Wang D, Au A, Gunnemann F, Hilely A, Scharf J, Tran K
. Pentosan-associated maculopathy: prevalence, screening guidelines, and spectrum of findings based on prospective multimodal analysis. Can J Ophthalmol. 2020; 55(2):116-125.
DOI: 10.1016/j.jcjo.2019.12.001.
View
13.
Ding H, Denniston A, Rao V, Gordon C
. Hydroxychloroquine-related retinal toxicity. Rheumatology (Oxford). 2015; 55(6):957-67.
DOI: 10.1093/rheumatology/kev357.
View
14.
. Erratum in: Pentosan Polysulfate Sodium Causes Diminished Function and Subtle Morphological Changes in Retina and RPE of Mice. Invest Ophthalmol Vis Sci. 2024; 65(4):47.
PMC: 11071688.
DOI: 10.1167/iovs.65.4.47.
View
15.
Jain N, Li A, Yu Y, VanderBeek B
. Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort. Br J Ophthalmol. 2019; 104(8):1093-1097.
PMC: 7288845.
DOI: 10.1136/bjophthalmol-2019-314765.
View
16.
Kalaw F, Ignacio J, Wu C, Ferreyra H, Nudleman E, Baxter S
. PENTOSAN POLYSULFATE SODIUM (ELMIRON) MACULOPATHY: A Genetic Perspective. Retina. 2023; 43(7):1174-1181.
DOI: 10.1097/IAE.0000000000003794.
View
17.
Robson A, Nilsson J, Li S, Jalali S, Fulton A, Tormene A
. ISCEV guide to visual electrodiagnostic procedures. Doc Ophthalmol. 2018; 136(1):1-26.
PMC: 5811581.
DOI: 10.1007/s10633-017-9621-y.
View
18.
Hatz K, Ebneter A, Tuerksever C, Pruente C, Zinkernagel M
. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features. Ophthalmologica. 2018; 239(4):205-214.
PMC: 6008872.
DOI: 10.1159/000485852.
View
19.
Romano F, Lamanna F, Gabrielle P, Teo K, Battaglia Parodi M, Iacono P
. Update on Retinal Vein Occlusion. Asia Pac J Ophthalmol (Phila). 2023; 12(2):196-210.
DOI: 10.1097/APO.0000000000000598.
View
20.
Blackorby B, Banda H, Smith B, Shah G
. Macular Findings of Patients on Pentosan Polysulfate Sodium. Mil Med. 2021; 188(3-4):e579-e583.
DOI: 10.1093/milmed/usab301.
View